Building genetic assessments into how we determine prognosis of ALL
EuroBloodNet European Reference Network - when will it be in place and why is collaboration crucial?
Joan Lluis Vives-Corrons et al.
Is denosumab superior to zoledronic acid in the treatment of bone metastases in MM?
How can we assess quality of life in AML patients?
New aims and next steps for adult ALL induction therapy